|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.72 USD | +4.31% |
|
+80.91% | -53.37% |
| 05-10 | Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-09 | Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease | CI |
April 29 (Reuters) -
Annovis Bio said on Monday that its Alzheimer's treatment showed significantly higher improvement in cognition in Alzheimer's patients during a mid-stage trial. (Reporting by Christy Santhosh; Editing by Vijay Kishore)
| 1st Jan change | Capi. | |
|---|---|---|
| -53.37% | 92.05M | |
| +7.52% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.58% | 16.81B | |
| +37.41% | 12.54B | |
| -23.95% | 8.09B |
ANNOVIS BIO, INC. 
